# Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

> **NCT00680225** · PHASE3 · COMPLETED · sponsor: **New England Retina Associates** · enrollment: 10 (actual)

## Conditions studied

- Choroidal Melanoma

## Interventions

- **DRUG:** Ranibizumab injection and TTT - ICG based

## Key facts

- **NCT ID:** NCT00680225
- **Lead sponsor:** New England Retina Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680225, "Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00680225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*